Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy

Karl T Butterworth; James R Nicol; Mihaela Ghita; Soraia Rosa; Pankaj Chaudhary; Conor K McGarry; Helen O McCarthy; Gloria Jimenez-Sanchez; Rana Bazzi; Stéphane Roux; Olivier Tillement; Jonathan A Coulter; Kevin M Prise

doi:10.2217/nnm-2016-0062

Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy

Karl T Butterworth, James R Nicol, Mihaela Ghita, Soraia Rosa, Pankaj Chaudhary, Conor K McGarry, Helen O McCarthy, Gloria Jimenez-Sanchez, Rana Bazzi, Stéphane Roux, Olivier Tillement, Jonathan A Coulter, Kevin M Prise

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

509 Downloads (Pure)

Abstract

AIM: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer.

MATERIALS & METHODS: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo.

RESULTS: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only.

CONCLUSION: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.

Original language	English
Pages (from-to)	2035-47
Number of pages	13
Journal	Nanomedicine
Volume	11
Issue number	16
Early online date	27 Jul 2016
DOIs	https://doi.org/10.2217/nnm-2016-0062
Publication status	Published - Aug 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/nnm-2016-0062Licence: CC BY-NC

Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy
© Coulter and coauthors 2016 This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 3.28 MBLicence: CC BY-NC

Karl Butterworth
- k.butterworthqub.acuk
- School of Medicine, Dentistry and Biomedical Sciences - Professor
- The Johnston Cancer Research Centre
Person: Academic
Jonathan Coulter
- j.coulterqub.acuk
- School of Pharmacy - Associate Dean of Postgraduate Research and Innovation
- Material and Advanced Technologies for Healthcare
Person: Academic

Cite this

Butterworth, K. T., Nicol, J. R., Ghita, M., Rosa, S., Chaudhary, P., McGarry, C. K., McCarthy, H. O., Jimenez-Sanchez, G., Bazzi, R., Roux, S., Tillement, O., Coulter, J. A., & Prise, K. M. (2016). Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy. Nanomedicine, 11(16), 2035-47. https://doi.org/10.2217/nnm-2016-0062

@article{915e193ef94a4f8e82170ff12d20291c,

title = "Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy",

abstract = "AIM: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer.MATERIALS \& METHODS: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo.RESULTS: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10\% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only.CONCLUSION: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.",

author = "Butterworth, \{Karl T\} and Nicol, \{James R\} and Mihaela Ghita and Soraia Rosa and Pankaj Chaudhary and McGarry, \{Conor K\} and McCarthy, \{Helen O\} and Gloria Jimenez-Sanchez and Rana Bazzi and St{\'e}phane Roux and Olivier Tillement and Coulter, \{Jonathan A\} and Prise, \{Kevin M\}",

year = "2016",

month = aug,

doi = "10.2217/nnm-2016-0062",

language = "English",

volume = "11",

pages = "2035--47",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Taylor and Francis",

number = "16",

}

TY - JOUR

T1 - Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy

AU - Butterworth, Karl T

AU - Nicol, James R

AU - Ghita, Mihaela

AU - Rosa, Soraia

AU - Chaudhary, Pankaj

AU - McGarry, Conor K

AU - McCarthy, Helen O

AU - Jimenez-Sanchez, Gloria

AU - Bazzi, Rana

AU - Roux, Stéphane

AU - Tillement, Olivier

AU - Coulter, Jonathan A

AU - Prise, Kevin M

PY - 2016/8

Y1 - 2016/8

N2 - AIM: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer.MATERIALS & METHODS: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo.RESULTS: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only.CONCLUSION: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.

AB - AIM: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer.MATERIALS & METHODS: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo.RESULTS: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only.CONCLUSION: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.

U2 - 10.2217/nnm-2016-0062

DO - 10.2217/nnm-2016-0062

M3 - Article

C2 - 27463088

SN - 1743-5889

VL - 11

SP - 2035

EP - 2047

JO - Nanomedicine

JF - Nanomedicine

IS - 16

ER -

Preclincial evaluation of Gold-DTDTPA Nanoparticles As Theranostic Agents In Prostate Cancer Radiotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Profiles

Karl Butterworth

Jonathan Coulter

Cite this